Pediatric Oncology Panel Highlights Trend Toward Being More Selective With Studies
FDA and the pediatric oncology community are becoming more selective in the cancer drugs they want studied in children.
FDA and the pediatric oncology community are becoming more selective in the cancer drugs they want studied in children.